Ali Etemadi

All Publications

• Kidney Denervation: Latest Breakthroughs and Insights. Clinical journal of the American Society of Nephrology : CJASN Bahrainwala, J. Z., Etemadi, A., Chang, T. I. 2025

  Abstract

  Kidney denervation has emerged as an interventional treatment for the ever-increasing prevalence of uncontrolled hypertension that recently garnered Unites States Food and Drug Administration approval. Kidney denervation is a minimally invasive catheter-based procedure that ablates the sympathetic nerves around the kidney arteries using a variety of modalities. Clinical trial data have generally demonstrated that kidney denervation is a safe procedure, but efficacy data are mixed. In addition, important populations were excluded from these trials, including patients with advanced chronic kidney disease and kidney transplants. Currently, it is still unclear which patients with hypertension will have an appropriate therapeutic effect after undergoing kidney denervation, and there is no available biomarker to assist in predicting a patient's blood pressure response after kidney denervation. When considering when to offer kidney denervation, patients should ideally be evaluated by a multidisciplinary team with the proper expertise to evaluate the appropriateness of the referral and discuss the risks and benefits to allow for shared decision-making. Ongoing and future studies will help to address current unanswered questions that remain about longer-term safety and efficacy of renal denervation, particularly in populations poorly represented by current trials. Kidney denervation can be an important therapy that can be used to complement antihypertensive medications and lifestyle changes to improve hypertension control.

  View details for DOI 10.2215/CJN.0000000972

  View details for PubMedID 41325144

• Acute elevated blood pressure in the inpatient setting. Heart (British Cardiac Society) Etemadi, A., Kumar, P., Anderson, T. S., Chang, T. I. 2025

  Abstract

  Elevated blood pressure (BP) in the inpatient setting is frequently encountered by most healthcare providers. While there is general consensus on the management of acute BP elevations when associated with end-organ damage, these cases of true hypertensive emergency are relatively infrequent. In contrast, asymptomatic acute BP elevations are considerably more frequent, yet there is little consensus on their appropriate management. Contributing factors include concerns about missing true emergencies, the barriers affecting the accuracy of inpatient BP measurements and a lack of consistent data on the short- and long-term impact of inpatient BP elevations. Practice varies widely, even between departments within the same hospital, and includes observation, intravenous antihypertensives, oral agents and adjustments to existing regimens. Some clinicians also choose to discharge patients on intensified therapy based on inpatient BP values. However, despite the high prevalence of elevated BP in the inpatient setting, evidence remains heterogeneous and fragmented. This review aims to synthesise current knowledge and provide a practical, holistic framework for evaluating and managing elevated BP in the inpatient setting.

  View details for DOI 10.1136/heartjnl-2025-325845

  View details for PubMedID 40962486

• Identifying peripheral artery disease in persons with and without chronic kidney disease from electronic health records. Vascular medicine (London, England) Parsons, G. R., Parvathinathan, G., Etemadi, A., Liu, S., Ross, E., Jones, W. S., Stedman, M. R., Chang, T. I. 2025: 1358863X251322182

  View details for DOI 10.1177/1358863X251322182

  View details for PubMedID 40028756

• Renal Denervation Effects on Blood Pressure in Resistant and Uncontrolled Hypertension: A Meta-Analysis of Sham-Controlled Randomized Clinical Trials. Clinical cardiology Soleimani, H., Sattartabar, B., Parastooei, B., Eshraghi, R., Nazari, R., Najdaghi, S., Hobaby, S., Etemadi, A., Mahalleh, M., Taheri, M., Hernandez, A. V., Kuno, T., Taheri, H., Siegel, R. J., Rader, F., Tehrani, B. N., Mandegar, M. H., Safaee, E., Ebrahimi, P., Hosseini, K. 2025; 48 (3): e70104

  Abstract

  Although some guidelines recommend Renal denervation (RDN) as an alternative to anti-HTN medications, there are concerns about its efficacy and safety. We aimed to evaluate the benefits and harms of RDN in a systematic review and meta-analysis of sham-controlled randomized clinical trials (RCT).Databases were searched until September 10th, 2024, to identify RCTs evaluating RDN for treating URH versus sham control. The primary outcomes were the change in office and ambulatory 24-h systolic (SBP) and diastolic blood pressure (DBP). Secondary outcomes were changes in daytime and nighttime SBP and DBP, home BP, number of anti-HTN drugs, and related complications. Mean differences (MD) and relative risks (RR) described the effects of RDN on BP and complications, respectively, using random effects meta-analyses. GRADE methodology was used to assess the certainty of evidence (COE).We found 16 included sham-controlled RCTs [RDN (n = 1594) vs. sham (n = 1225)]. RDN significantly reduced office SBP (MD -4.26 mmHg, 95% CI: -5.68 to -2.84), 24 h ambulatory SBP (MD -2.63 mmHg), office DBP (MD -2.15 mmHg), 24-h ambulatory DBP (MD -1.27 mmHg), and daytime SBP and DBP (MD -3.29 and 2.97 mmHg), compared to the sham. The rate of severe complications was low in both groups (0%-2%). The heterogeneity was high among most indices, and CoE was very low for most outcomes.RDN significantly reduced several SBP and DBP outcomes versus sham without significantly increasing complications. This makes RDN a potentially effective alternative to medications in URH.

  View details for DOI 10.1002/clc.70104

  View details for PubMedID 40022571

• Association between sleep duration and hypertension incidence: Systematic review and meta-analysis of cohort studies PLOS ONE Hosseini, K., Soleimani, H., Tavakoli, K., Maghsoudi, M., Heydari, N., Farahvash, Y., Etemadi, A., Najafi, K., Askari, M. K., Gupta, R., Hakim, D., Rahimi, K. 2024; 19 (7): e0307120

  Abstract

  Sleep duration has been suggested to be associated with hypertension (HTN). However, evidence of the nature of the relationship and its direction has been inconsistent. Therefore, we performed a meta-analysis to assess the relationship between sleep duration and risk of HTN incidence, and to distinguish more susceptible populations.PubMed, Embase, Scopus, Web of Science, and ProQuest were searched from January 2000 to May 2023 for cohort studies comparing short and long sleep durations with 7-8 hours of sleep for the risk of HTN incidence. Random-effect model (the DerSimonian-Laird method) was applied to pool risk ratios (RR) and 95% confidence interval (CI).We included sixteen studies ranging from 2.4 to 18 years of follow-up duration evaluating HTN incidence in 1,044,035 people. Short sleep duration was significantly associated with a higher risk of developing HTN (HR: 1.07, 95% CI: 1.06-1.09). The association was stronger when the sleep duration was less than 5 hours (HR: 1.11, 95% CI: 1.08-1.14). In contrast to males, females (HR: 1.07, 95% CI: 1.04-1.09) were more vulnerable to developing HTN due to short sleep duration. No significant difference between different follow-up durations and age subgroups was observed. Long sleep duration was not associated with an increased incidence of HTN.Short sleep duration was associated with higher risk of HTN incidence, however, there was no association between long sleep duration and incidence of HTN. These findings highlight the importance of implementing target-specific preventive and interventional strategies for vulnerable populations with short sleep duration to reduce the risk of HTN.

  View details for DOI 10.1371/journal.pone.0307120

  View details for Web of Science ID 001282347100032

  View details for PubMedID 39008468

  View details for PubMedCentralID PMC11249221

• Revisiting Antioxidants in CKD: Still No Consensus. American journal of kidney diseases : the official journal of the National Kidney Foundation Etemadi, A., Chang, T. I. 2024

  View details for DOI 10.1053/j.ajkd.2024.06.009

  View details for PubMedID 38992459